Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.41 |
| ▸ | ADH1B | P00325 | 1/20 | 0.40 |
| ▸ | ADH1C | P00326 | 1/20 | 0.40 |
| ▸ | ADH1A | P07327 | 1/20 | 0.40 |
| ▸ | ADH7 | P40394 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7456364 | 0.78 | AOC3 (0.55) | AOC3ALDH1A1NPC1RAB9ATDP1 | |
| SCHEMBL1669089 | 0.78 | LOXL2 (0.43) | AOC3ALDH1A1LOXL2 | |
| SCHEMBL8525708 | 0.78 | AOC3 (0.30) | AOC3 | |
| SCHEMBL3251335 | 0.77 | AOC3 (0.52) | AOC3CA2ALDH1A1TSHRCARM1 | |
| SCHEMBL23337476 | 0.77 | AOC3 (0.42) | AOC3CA2ALDH1A1TSHRNPC1 | |
| SCHEMBL6233069 | 0.77 | PNMT (0.50) | AOC3TSHRKDM4E | |
| SCHEMBL26802 | 0.76 | ALDH1A1 (0.48) | AOC3CA2ALDH1A1TSHRADH1B | |
| SCHEMBL28570283 | 0.76 | ALDH1A1 (0.51) | AOC3CA2ALDH1A1TSHRADH1B | |
| SCHEMBL6231688 | 0.75 | LOXL2 (0.50) | CA2NPC1CA12CA9LOXL2 | |
| SCHEMBL6232723 | 0.75 | AOC3 (0.58) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024047172-A1 | AN INTEGRIN ALPHA10 ANTIBODY DRUG CONJUGATE | TARGINTA AB (SE) | 2024-03-07 | — | — | WO | claimed |
| EP-3606922-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | Hangzhou Dac Biotech Co., Ltd (CN) | 2020-02-12 | — | — | EP | claimed |
| CN-109689107-A | Derivatives of amatoxins and their coupling to cell binding molecules | 杭州多禧生物科技有限公司 | 2019-04-26 | — | — | CN | claimed |
| WO-2018185526-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2018-10-11 | — | — | WO | claimed |
| EP-3152223-A1 | PEPTIDE-DRUG CONJUGATES | Jiarui Biopharmaceuticals, Ltd. (CN) | 2017-04-12 | — | — | EP | claimed |
| EP-3041846-A1 | NOVEL CYTOTOXIC AGENTS FOR CONJUGATION OF DRUGS TO CELL BINDING MOLECULE | Hangzhou Dac Biotech Co., Ltd (CN) | 2016-07-13 | — | — | EP | claimed |
| WO-2015187540-A1 | PEPTIDE-DRUG CONJUGATES | CHU SHAOSONG (US) | 2015-12-10 | — | — | WO | claimed |
| WO-2015028850-A1 | NOVEL CYTOTOXIC AGENTS FOR CONJUGATION OF DRUGS TO CELL BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2015-03-05 | — | — | WO | claimed |
| EP-1812465-A1 | NOVEL COMPOSITION AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES | Genentech, Inc. (US) | 2007-08-01 | — | — | EP | claimed |
| WO-2006054961-A2 | NOVEL COMPOSITION AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES | GENENTECH, INC. (US) | 2006-05-26 | — | — | WO | claimed |
| WO-2024047172-A1 | AN INTEGRIN ALPHA10 ANTIBODY DRUG CONJUGATE | TARGINTA AB (SE) | 2024-03-07 | — | — | WO | disclosed |
| EP-4232095-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | Araris Biotech AG (CH) | 2023-08-30 | — | — | EP | disclosed |
| WO-2023072934-A1 | METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | ARARIS BIOTECH AG (CH) | 2023-05-04 | — | — | WO | disclosed |
| CN-108093640-B | Site-specific antibody-drug conjugates | ADC治疗股份有限公司 | 2022-05-17 | — | — | CN | disclosed |
| WO-2022084560-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | ARARIS BIOTECH AG (CH) | 2022-04-28 | — | — | WO | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-0947510-B1 | Process for the preparation of 1,3,4-trisubstituted 1,2,4-triazolium salts | BASF AG (DE) | 2002-02-13 | — | — | EP | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-6046360-A | REDUCTIVE AMINATION OF CYCLOHEXANONES USING HYDROGEN, SOLVENT, BENZYLIC AMINE AND CATALYST OF NICKEL OR A PLATINUM METAL; DESOLVENTIZING; TREATING WITH THE SAME CATALYST TO PRODUCE THE TITLE PRODUCT; CATALYST STEREOSELECTIVITY | HOECHST SCHERING AGREVO GMBH (DE) | 2000-04-04 | — | — | US | disclosed |
| EP-0947510-A1 | Process for the preparation of 1,3,4-trisubstituted 1,2,4-triazolium salts | BASF AKTIENGESELLSCHAFT (DE) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | AOC3 662/4885CA2 1149/4885ALDH1A1 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.